Literature DB >> 32032100

Neuroprotective effect of chronic administration of cannabidiol during the abstinence period on methamphetamine-induced impairment of recognition memory in the rats.

Yasaman Razavi1, Ronak Shabani1,2, Mehdi Mehdizadeh2, Abbas Haghparast3.   

Abstract

Neuropsychiatric disorders, such as addiction, are associated with cognitive impairment, including learning and memory deficits. Previous research has demonstrated that the chronic use of methamphetamine (METH) induces long-term cognitive impairment and cannabidiol (CBD), as a neuroprotectant, can reverse spatial memory deficits induced by drug abuse. The study aimed to evaluate the effect of CBD on METH-induced memory impairment in rats chronically exposed to METH (CEM). For the induction of CEM, animals received METH (2 mg/kg, twice/day) for 10 days. Thereafter, the effect of intracerebroventricular (ICV) administration of CBD (32 and 160 nmol) during the (10 days) abstinence period on spatial memory was evaluated using the Y-Maze test, while recognition memory was examined using the novel object recognition (NOR) test. The results revealed a significant increase in the motor activity of METH-treated animals compared with the control group and, after the 10-day abstinence period, motor activity returned to baseline. Notably, the chronic administration of METH had impairing effects on spontaneous alternation performance and recognition memory, which was clearly observed in the NOR test. Additionally, although the ICV administration of CBD (160 nmol) could reverse long-term memory, a lower dose (32 nmol) did not result in any significant increase in exploring the novel object during short-term memory testing. These novel findings suggest that the chronic administration of METH induces memory impairment and presents interesting implications for the potential use of CBD in treating impairment deficits after chronic exposure to psychostimulant drugs such as METH.

Entities:  

Year:  2020        PMID: 32032100     DOI: 10.1097/FBP.0000000000000544

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  7 in total

1.  Involvement of Hippocampal D1-Like Dopamine Receptors in the Inhibitory Effect of Cannabidiol on Acquisition and Expression of Methamphetamine-Induced Conditioned Place Preference.

Authors:  Kiana Nouri; Mahsa Anooshe; Saeideh Karimi-Haghighi; Zahra Mousavi; Abbas Haghparast
Journal:  Neurochem Res       Date:  2021-05-15       Impact factor: 3.996

2.  Cannabidiol attenuates methamphetamine-induced cardiac inflammatory response through the PKA/CREB pathway in rats.

Authors:  Qianyun Nie; Wenjuan Dong; Baoyu Shen; Genmeng Yang; Hao Yu; Ruilin Zhang; Yanxia Peng; Yang Yu; Shijun Hong; Lihua Li
Journal:  Ann Transl Med       Date:  2022-09

Review 3.  Cannabidiol and substance use disorder: Dream or reality.

Authors:  Saeideh Karimi-Haghighi; Yasaman Razavi; Daniela Iezzi; Andrew F Scheyer; Olivier Manzoni; Abbas Haghparast
Journal:  Neuropharmacology       Date:  2022-01-13       Impact factor: 5.273

Review 4.  Therapeutic Effects of Cannabidiol on Methamphetamine Abuse: A Review of Preclinical Study.

Authors:  Yasaman Razavi; Fariborz Keyhanfar; Ronak Shabani; Abbas Haghparast; Mehdi Mehdizadeh
Journal:  Iran J Pharm Res       Date:  2021       Impact factor: 1.696

Review 5.  Co-exposure of cannabinoids with amphetamines and biological, behavioural and health outcomes: a scoping review of animal and human studies.

Authors:  Dimitri Daldegan-Bueno; Lucas O Maia; Michelle Glass; Didier Jutras-Aswad; Benedikt Fischer
Journal:  Psychopharmacology (Berl)       Date:  2021-10-06       Impact factor: 4.415

6.  Cannabidiol promotes neurogenesis in the dentate gyrus during an abstinence period in rats following chronic exposure to methamphetamine.

Authors:  Yasaman Razavi; Fariborz Keyhanfar; Abbas Haghparast; Ronak Shabani; Mehdi Mehdizadeh
Journal:  Metab Brain Dis       Date:  2021-06-18       Impact factor: 3.584

Review 7.  Role of Cannabidiol in the Therapeutic Intervention for Substance Use Disorders.

Authors:  Francisco Navarrete; María Salud García-Gutiérrez; Ani Gasparyan; Amaya Austrich-Olivares; Jorge Manzanares
Journal:  Front Pharmacol       Date:  2021-05-20       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.